ECSP066595A - Anticuerpo del receptor anti-igf-i - Google Patents
Anticuerpo del receptor anti-igf-iInfo
- Publication number
- ECSP066595A ECSP066595A EC2006006595A ECSP066595A ECSP066595A EC SP066595 A ECSP066595 A EC SP066595A EC 2006006595 A EC2006006595 A EC 2006006595A EC SP066595 A ECSP066595 A EC SP066595A EC SP066595 A ECSP066595 A EC SP066595A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- igf
- cancer
- receptor
- elevated levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/729,441 US8034904B2 (en) | 2002-06-14 | 2003-12-08 | Anti-IGF-I receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066595A true ECSP066595A (es) | 2006-10-17 |
Family
ID=36616549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006595A ECSP066595A (es) | 2003-12-08 | 2006-05-31 | Anticuerpo del receptor anti-igf-i |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1692176A4 (pt) |
JP (1) | JP2008502589A (pt) |
KR (1) | KR20070001883A (pt) |
CN (1) | CN1886424A (pt) |
AU (1) | AU2004303792A1 (pt) |
BR (1) | BRPI0417406A (pt) |
CA (1) | CA2548065A1 (pt) |
CR (1) | CR8426A (pt) |
EA (1) | EA009807B1 (pt) |
EC (1) | ECSP066595A (pt) |
IL (1) | IL174770A0 (pt) |
MX (1) | MXPA06005540A (pt) |
NO (1) | NO20063155L (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG2014011340A (en) | 2009-12-21 | 2014-07-30 | Genentech Inc | Antibody formulation |
JP2013529076A (ja) * | 2010-05-11 | 2013-07-18 | アベオ ファーマシューティカルズ, インコーポレイテッド | 抗fgfr2抗体 |
WO2013055699A1 (en) * | 2011-10-10 | 2013-04-18 | Children's Hospital Los Angeles | Novel asparaginase and methods for treating diseases associated with asparagine dependence |
CN103509117B (zh) * | 2013-05-06 | 2016-03-09 | 江苏匡亚生物医药科技有限公司 | 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途 |
AR112600A1 (es) * | 2017-05-30 | 2019-11-20 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2351452A1 (en) * | 1998-12-04 | 2000-06-15 | Novartis Ag | Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3 |
PT1399483E (pt) * | 2001-01-05 | 2010-07-20 | Pfizer | Anticorpos contra o receptor do factor i de crescimento tipo insulina |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
JP2006517581A (ja) * | 2003-02-13 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗インスリン様増殖因子i受容体抗体の使用 |
-
2004
- 2004-12-07 JP JP2006543832A patent/JP2008502589A/ja active Pending
- 2004-12-07 CA CA002548065A patent/CA2548065A1/en not_active Abandoned
- 2004-12-07 AU AU2004303792A patent/AU2004303792A1/en not_active Abandoned
- 2004-12-07 CN CNA200480034889XA patent/CN1886424A/zh active Pending
- 2004-12-07 MX MXPA06005540A patent/MXPA06005540A/es active IP Right Grant
- 2004-12-07 KR KR1020067010010A patent/KR20070001883A/ko not_active Application Discontinuation
- 2004-12-07 EP EP04811082A patent/EP1692176A4/en not_active Ceased
- 2004-12-07 BR BRPI0417406-2A patent/BRPI0417406A/pt not_active IP Right Cessation
- 2004-12-07 EA EA200600931A patent/EA009807B1/ru not_active IP Right Cessation
-
2006
- 2006-04-04 IL IL174770A patent/IL174770A0/en unknown
- 2006-05-31 EC EC2006006595A patent/ECSP066595A/es unknown
- 2006-06-01 CR CR8426A patent/CR8426A/es not_active Application Discontinuation
- 2006-07-07 NO NO20063155A patent/NO20063155L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0417406A (pt) | 2007-04-03 |
CN1886424A (zh) | 2006-12-27 |
KR20070001883A (ko) | 2007-01-04 |
AU2004303792A1 (en) | 2005-07-07 |
MXPA06005540A (es) | 2006-08-17 |
CA2548065A1 (en) | 2005-07-07 |
JP2008502589A (ja) | 2008-01-31 |
NO20063155L (no) | 2006-08-11 |
EP1692176A4 (en) | 2008-11-12 |
CR8426A (es) | 2007-12-04 |
EP1692176A1 (en) | 2006-08-23 |
EA009807B1 (ru) | 2008-04-28 |
EA200600931A1 (ru) | 2006-10-27 |
IL174770A0 (en) | 2006-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG141243A1 (en) | Anti-igf-i receptor antibody | |
AR061911A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
CL2017001580A1 (es) | Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped. | |
ES2571235T3 (es) | Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3 | |
MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
UA94388C2 (ru) | Антиинтегриновый иммуноконьюгат и способы лечения с его помощью | |
NO20070945L (no) | Induksjon av apoptose i tumorceller som uttrykker toll-lignende reseptor | |
AR061245A1 (es) | Composiciones y metodos para la modulacion del desarrollo vascular | |
ECSP066595A (es) | Anticuerpo del receptor anti-igf-i | |
CU20130130A7 (es) | Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2 | |
DOP2013000045A (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
WO2007100640A3 (en) | Growth hormone receptor antagonist cancer treatment | |
EA032908B1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
NZ599707A (en) | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ) | |
MX2021011750A (es) | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. | |
EA200601405A1 (ru) | Гуманизированное антитело | |
EA202193309A1 (ru) | Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы | |
MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
CO6331345A2 (es) | Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma | |
DOP2009000003A (es) | Anticuerpo antagonista para el tratamiento del cancer | |
Sandomenico | 3D1, a novel anti-nodal monoclonal antibody to target melanoma | |
PE20091437A1 (es) | Anticuerpos modificadores de enfermedades cancerosas |